Introduction
Several thrombotic complications accompany percutaneous coronary intervention (PCI), one of which is the no-reflow phenomenon, defined as inadequate myocardial perfusion without any evidence of mechanical obstruction in a sufficiently dilated coronary vessel. No-reflow is associated with poor outcomes and a novel 'MAP strategy' was designed to prevent it. 'MAP' implies (i) Maximum aspiration of atherothrombus, (ii) Adjuvant utilization of GP IIb/IIIa inhibitor, and (iii) Prolonged inflation of the balloon/stent. This study is a i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) s 4 3 -s 4 6 a r t i c l e i n f o 
2.2.
Thrombus aspiration, pharmacotherapy, and stent implantation PCI was performed using standard techniques; femoral approach was used. A loading dose of clopidogrel (300 mg) and aspirin (350 mg) was administered on admission. Unfractionated heparin (100 units/kg) and tirofiban bolus (0.4 mg/kg/ min) for 30 min, followed by an infusion (0.15 mg/kg/min) for 12 h, were administered during the procedure.
Multiple passes (minimum two) of thrombus aspiration were carried out, using a 6F thrombuster aspiration catheter (Kaneka Medix, Japan) or 6F Export aspiration catheter (Medtronic, Danvers, USA) (Fig. 1) . Predilatation was carried out if needed by inflating the balloon quickly till disappearance of the waist, keeping it inflated at 1-2 atm higher for 35 s, and later deflating it quickly. The balloon diameter was 0.5 mm less than the vessel diameter. Stents lesser than 20 mm in length were deployed at 14-18 atm. When residual stenosis was ≥20%, or when stents of ≥20 mm length were used, postdilatation with 10-12 mm length balloon was carried out at 14-18 atm. Prolonged (35-s) inflation of stent was done only in case of direct stenting.
2.3.
Measurement of endpoints was recorded just before, 6 h after, and 24 h after, the procedure. Two-dimensional echocardiography was performed prior to the procedure, at the time of discharge, and at 9-month follow-up. Follow-up data were obtained at the end of 1, 3, and 9 months after the procedure.
Results
The Following the 'MAP strategy', no patient showed TIMI grade 0 or 1 flow (no-reflow) ( Table 1) . Successful reperfusion (MBG 3 or 2) and significant STE recovery (>50% ST-segment resolution (STR)) were achieved in 62 (87.32%) and 51 (71.83%) patients, respectively ( Table 2 ). The mean (AESD) LVEF measured by two-dimensional echocardiography improved by 6.76-50.56% (AE8.68%) at 9-month follow-up.
Two patients had minor dissections during aspiration, which were tackled by the stent. Other than a case of congestive cardiac failure after 6 months, no complications, such as reinfarction, and angina requiring revascularization at months 1, 3, and 9, were reported. Neither death nor rehospitalization was reported up to the 9-month follow-up. 
'M': Maximum aspiration
No complications, such as stroke, coronary perforation, or thrombus dislodgement, were reported in this study. Notwithstanding the sample size and study design, the death rate at 9 months in the present study (no death) was at least numerically lower to that observed at 12 months in the aspiration arm of the TAPAS 3 study (3.6%). The incidence of partial STR in the present study [51 (72%) patients] too is similar to the EXPIRA 4 trial (63% patients).
TIMI grade 3 flow in 89% cases is comparable to the incidence of TIMI grade 3 flow in 86% cases in the TAPAS 3 trial.
'A': Adjunctive glycoprotein IIb/IIIa inhibitors
Previous findings of positive associations [5] [6] [7] [8] [9] with glycoprotein IIb/IIIa inhibitors are congruent with our results in that up to 9 months after the PCI, no death, reinfarction, or target vessel revascularization was reported. Furthermore, none of the subjects in the present study encountered any major bleeding episode.
'P': Prolonged balloon inflation
While thrombus aspiration acts on the intraluminal thrombus, glycoprotein IIb/IIIa inhibitors act at the microvascular level. Effectively, the first two components ('M' and 'A') address intraluminal and microvascular thrombus. It is postulated that the third component ('P') addresses intralesional thrombus. Rapid balloon inflation and deflation abruptly disrupts and fragments the atheromatous material and results in distal microembolization, as well as platelet activation, contributing to acute occlusion. On the contrary, it is speculated that the prolonged inflation possibly compresses the intralesional plaque against the arterial wall and entraps it under the stent struts, thus leading to reduced intravascular as well as intracapillary thrombus burden.
Limitations
First, the sample was small and belonged to a single center, and may not accurately represent diverse cases. Second, the 'MAP strategy' was not compared with a control group, which makes it difficult to state whether the observed favorable outcomes were superior, equivalent, or inferior to PCI alone. i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) s 4 3 -s 4 6 Third, the analysis was retrospective, and could be confounded by several variables. Lastly, complex patients were not included.
Key messages
The most interesting aspect of the 'MAP strategy' was that it resulted in zero cases of TIMI flow grade 0 or 1 ('no-reflow'). The 'MAP strategy' is technically feasible and safe to implement in day-to-day practice. Addition of a simple step of prolonged inflation can improve angiographic and clinical outcomes; however, this concept needs to be tested in large, controlled studies.
